Table 1.
Clinicopathological factors of 544 patients who underwent radical hepatectomy
| Variables | Training cohort (n = 381) | Validation cohort (n = 163) | P |
|---|---|---|---|
| Age, years | 51.3 ± 11.2 | 50.2 ± 11.5 | 0.301 |
| Sex | 0.410 | ||
| Male | 324 (85.0%) | 143 (87.7%) | |
| Female | 57 (15.0%) | 20 (12.3%) | |
| BMI, Kg/m2 | 0.713 | ||
| < 18.5 | 27 (7.1%) | 12 (7.4%) | |
| 18.5–25 | 258 (67.7%) | 116 (71.2%) | |
| ≥ 25 | 96 (25.2%) | 35 (21.5%) | |
| HBsAg | 0.327 | ||
| Positive | 328 (86.1%) | 135 (82.8%) | |
| Negative | 53 (13.9%) | 28 (17.2%) | |
| HBV-DNA (copies/ml) | |||
| < 103 | 176 (46.2%) | 79 (48.5%) | 0.645 |
| ≥ 103 | 205 (53.8%) | 84 (51.5%) | |
| Liver cirrhosis | 0.142 | ||
| Present | 263 (69.0%) | 102 (62.6%) | |
| Absent | 118 (31.0%) | 61 (37.4%) | |
| Child-Pugh classification | 0.204 | ||
| A | 367 (96.3%) | 161 (98.8%) | |
| B | 14 (3.7%) | 2 (1.2%) | |
| Previous abdominal surgery | 0.705 | ||
| Present | 61 (16.0%) | 24 (14.7%) | |
| Absent | 320 (84.0%) | 139 (85.3%) | |
| Comorbidities | 0.012 | ||
| Present | 73 (19.2%) | 17 (10.4%) | |
| Absent | 308 (80.8%) | 146 (89.6%) | |
| AFP, ng/mL | 0.091 | ||
| < 400 | 233 (61.2%) | 87 (53.4%) | |
| ≥ 400 | 148 (38.8%) | 76 (46.6%) | |
| CEA, ng/mL | 0.575 | ||
| Normal | 297 (78.0%) | 131 (80.4%) | |
| Abnormal | 84 (22.0%) | 32 (19.6%) | |
| CA19–9, U/ml | 0.588 | ||
| Normal | 233 (61.2%) | 104 (63.8%) | |
| Abnormal | 148 (38.8%) | 59 (36.2%) | |
| TBIL, umol/L | 14.0 (10.9–17.8) | 13.7 (11.0–18.4) | 0.794 |
| DBIL, umol/L | 5.4 (4.1–6.8) | 5.3 (4.2–6.8) | 0.853 |
| ALT, IU/L | 38.0 (27.0–56.8) | 39.0 (25.0–62.0) | 0.974 |
| AST, IU/L | 38.0 (30.0–58.0) | 39.0 (30.0–59.0) | 0.875 |
| Albumin, g/L | 0.909 | ||
| <35 | 27 (7.1%) | 12 (7.4%) | |
| ≥ 35 | 354 (92.9%) | 151 (92.6%) | |
| NLR | 2.2 (1.7–3.1) | 2.3 (1.6–3.2) | 0.776 |
| PLR | 92.9 (65.1–128.3) | 84.7 (64.0–135.9) | 0. |
| ASA grade | 0.088 | ||
| II | 316 (82.9%) | 125 (76.7%) | |
| III | 65 (17.1%) | 38 (23.3%) | |
| Largest tumor size, cm | 5.0 (3.2–7.8) | 5.6 (3.4–9.0) | 0.106 |
| Tumor number | 0.965 | ||
| Solitary | 358 (94.0%) | 153 (93.9%) | |
| Multiple | 23 (6.0%) | 10 (6.1%) | |
| Hepatectomy | 0.297 | ||
| Anatomical | 213 (55.9%) | 99 (60.7%) | |
| Nonanatomical | 168 (44.1%) | 64 (39.3%) | |
| Hemorrhage, ml | 0.498 | ||
| <200 | 133 (34.9%) | 52 (31.9%) | |
| ≥ 200 | 248 (65.1%) | 111 (68.1%) | |
| Intraoperative transfusion | 0.606 | ||
| Yes | 30 (7.9%) | 15 (9.2%) | |
| No | 351 (92.1%) | 148 (90.8%) | |
| Differentiation | 0.927 | ||
| poor | 169 (44.4%) | 73 (44.8%) | |
| Well-moderate | 212 (55.6%) | 90 (55.2%) | |
| MVI | 0.477 | ||
| Present | 124 (32.5%) | 48 (29.4%) | |
| Absent | 257 (67.5%) | 115 (70.6%) | |
| Capsule | 0.789 | ||
| Incomplete | 215 (56.4%) | 94 (57.7%) | |
| Complete | 166 (43.6%) | 69 (42.3%) |
ASA American Society of Anesthesiologists, BMI Body mass index, AFP α-fetoprotein, ALT Alanine transaminase, AST Aspartate aminotransferase, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet lymphocyte ratio, MVI Microvascular invasion